ONE Life Sciences Network – Investment and Life Sciences

Dr Jamie Coleman technology and life sciences guru will be our guest at the next ONE Life Sciences network meeting in Aberdeen on 3rd September 2019.

Jamie began his career in Cardiovascular Drug Discovery before setting up his own software companies and helping others to build their own software businesses. He is Founder and Chair of CodeBase, the UK’s largest tech incubator. CodeBase companies have raised in excess of half a billion dollars of investment and created over 700 jobs in Edinburgh in the last 3 years. He was CoFounder of Accelerated Digital Ventures, a £150M venture capital fund. He is currently CoFounder and COO of UltraHuman, an Immuno Oncology Drug Discovery company developing best in class antibodies to treat multiple cancers. He has been involved for many years in the intersection between software, healthcare and finance.

Life sciences is a key growth sector for North East Scotland with proven strengths in biologics, health data science, drug discovery and medtech. ONE Life Sciences, the sector board of private sector economic development body Opportunity North East (ONE), is acting and investing to double the number of companies in the region through the development and delivery of the £40m Bio-therapeutics Hub for Innovation investment project in Aberdeen, which will open in 2021. The Bio Hub, led by ONE, is backed with £20m of capital funding from the UK Government and Scottish Government through the Aberdeen City Region Deal, a partnership between Aberdeen City Council, Aberdeenshire Council and ONE. ONE has also committed £3.6m of its own funding over seven years to operate the Bio Hub and deliver bespoke commercialisation and growth support in the sector.

ONE works with companies and partners, including the University of Aberdeen, Robert Gordon University and NHS Grampian, to create links between academics, clinicians and industry to build the cluster and its ambition.

You must register to attend this free event. Please share this invitation with colleagues and contacts within the academic, clinical and commercial life sciences community in North East Scotland. Priority is given to attendees from these groups in the event of oversubscription.